Abstract

Introduction

Materials & Methods

Results

Discussion & Conclusion

References

Discussion
Board

1. Alcain FJ, Low H, Crane FL: Iron reverses impermeable chelator inhibition of DNA synthesis in CCL 39 cells. Proc. Natl. Acad. Sci. 91: 7903, 1994 (a)
2. Alcain FJ, Low H, Crane FL: Iron at the cell surface controls DNA synthesis in CCL 39 cells. Biochem. Biophys. Res. Commun. 203: 16, 1994 (b)
3. Alcain FJ, Low H, Crane FL: Inhibition of DNA synthesis in CCL 39 cells by impermeable iron chelators. Biochem. Mol. Biol. Int. 41: 303, 1997
4. Baker E, Vitolo ML, Webb JM: Iron chelation by pyridoxal isonicotinoyl hydrazone and annalogues in hepatocytes in culture. Biochem. Pharmacol. 34: 3011, 1985
5. Baker E, Richardson DR, Gross S, Ponka P: Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15: 492 1992
6. Becton DL, Bryles P:Desferrioxamine inhibition of human neuroblastoma viability and proliferation. Cancer Research 48: 7189,1988
7. Blatt J, Taylor SR, Stitely S: Mechanisms of antineuroblastoma activity of desferrioxamine in vitro. J. Lab. Clin. Med. 112: 433,1988
8. Blatt JT, Kontoghioghes GJ: Comparison of activity of desferrioxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Research 49: 2925, 1989
9. Bridges KR, Cudkowicz A: Effect of iron chelators on the transferrin receptor in K562 cells. J. Biol. Chem. 259: 12970, 1984
10. Crane FL, Sun IL, Clarke MG, Grebing C, Low H: Transplasma-membrane redox systems in growth and development. Biochim. Biophys. Acta 811: 233, 1985
11. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L: Effects of a single course of desferrioxamine in neuroblastoma patients. Cancer Research 50: 4929, 1990
12. Estrov Z, Tawa A, Zwang X-H,Dube ID, Sulh H, Cohen A, Gelfand EW, Freedman MH: In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood 69: 757, 1987
13. Goldenberg H, Dodel B, Seidl D: Plasma membrane Fe2-transferrin reductase and iron uptake in K562 cells are not directly related. Eur. J. Biocehm. 11: 475, 1990
14. Hann HL, Stahlhut MW, Hann CL: Effects of iron and desferrioxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 11: 566, 1990
15. Kaplinsky Z, Freedman MH, Gelfrand EW, Cohen A: Effect of desferrioxamine on DNA synthesis, DNA repair, cell proliferation and differentiation of HL-60 cells. Leukemia 1: 437, 1987
16. Kemp K, Kanner LJ, Francisco G, Thorson JA, Naulmann PW: Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator desferrioxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood 76: 991, 1990
17. Kontoghioghes GJ, Evans RW: Site specificity of iron removal from transferrin by a-ketohydroxypyridone chelators. FEBS Lett. 189: 141, 1985
18. Morgan EH: A study of iron transfer from rabbit transferrin to reticulocytes using synthetic chelating agents. Biochim. Biophys. Acta 244: 103, 1971
19. Morgan EH: Failure of a cell-free system from rabbit reticulocytes to remove iron from transferrin. Biochem. J. 158: 489, 1976
20. Mostert LJ, van Dorst JALM, Koster JF, van Eijk HG, Kontoghioghes GJ: Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte. Free Rad. Res. Commun. 3: 379, 1987
21. Nastruzzi P, Menegatti E, Gambari R: Differential effects of liposome-entrapped desferrioxamine on proliferation and erythroid differentiation of murine Erythroleulemic Friend cells. Biochim. Biophys. Acta 1013: 36, 1989
22. Nunez MT, Cole ES, Glass J: The reticulocyte plasma membrane pathway of iron uptake as determined by the mechanisms of aa-Dipyriyl inhibition. J. Biol. Chem 258: 1146, 1983
23. Richardson DR, Baker E: Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake. J. Cell. Physiol. 161: 160, 1994
24. Richardson DR, Milnes K: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: The mechanism of actin of ligands derived from salicyladehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89: 3025, 1997
25. Richardson DR, Ponka P, Baker E: The effect of the iron (III) chelator, deferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Research 54: 685, 1994
26. Richardson DR, Tran E, Ponka P: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86: 4295, 1995
27. Teatle R, Honeysett JM, Bergeron R: Combination iron depletion therapy. J. Natl. Cancer Inst. 81: 1229, 1989
28. Trinder D, Morgan EH, Baker E: The mechanisms of iron uptake by fetal hepatocytes in culture. Hepatology 6: 852, 1986

Back to the top.